Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More
ZacksLLY’s phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA’s updated COVID-19 vaccine.
LLY’s phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA’s updated COVID-19 vaccine.